Abstracts tagged "Spondyloarthropathies"

Abstract Number: 2690 • ACR Convergence 2025
Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
Lihi Eder¹, Sohan Shahab², Sarah Hopkins Gillespie³, Laura Bumbulis⁴, Helen Emanoilidis⁵, Charlene Compher⁶, Jose Scher⁷, Dafna D. Gladman⁸, Richard Cook⁴, Vinod Chandran¹ and Alexis Ogdie⁹, ¹University of Toronto, Toronto, ON, Canada, ²Women’s College Research Institute, Women’s College Hospital, Toronto, Canada, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Waterloo, Waterloo, Canada, ⁵Women’s College Hospital, Toronto, Canada, ⁶University of Pennsylvania School of Nursing and Hospital of the University of Pennsylvania, Philadelphia, ⁷New York University School of Medicine, New York, NY, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: The Dietary Interventions in Psoriatic Arthritis (DIPSA) study is a multicentre randomized controlled trial (RCT) designed to evaluate the efficacy of two personalized dietary…
Abstract Number: 2312 • ACR Convergence 2025
Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis
Faria Sami¹, Maria I. ("Maio") Danila², Liron Caplan³ and Rouhin Sen⁴, ¹The University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ³Medicine Service, Rocky Mountain Regional VAMC, Aurora, CO, ⁴University of Alabama at Birmingham, Department of Medicine, Division of Clinical Immunology & Rheumatology, Birmingham
Background/Purpose: Inflammatory bowel disease (IBD)-associated arthritis (IBD-A) can affect 24-44% of IBD patients and may represent an enhanced inflammatory state. IBD-A patients often experience a…
Abstract Number: 0568 • ACR Convergence 2025
Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
caroline Damen¹, Philippe Carron², Ann-Sophie De Craemer³, Filip Van den Bosch³ and Dirk Elewaut⁴, ¹Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ²Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁴VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium
Background/Purpose: Peripheral spondyloarthritis (pSpA) is a neglected clinical entity with few therapeutic or clinical management trials available to date. In the CRESPA-trial (1) very early…
Abstract Number: 0099 • ACR Convergence 2025
Time course and impact of IL17A on hepatic inflammation and fibrosis in adjuvant induced arthritis
Arthur Dollinger¹, Frédéric Meyer¹, Hélène Martin², Céline Delougeot³, Delphine Weil-Verhoeven¹ and Frank Verhoeven⁴, ¹CHU Besancon, Besancon, France, ²Université Marie et Louis Pasteur, Besancon, France, ³université Marie et Louis Pasteur, Besancon, ⁴CHU de Besançon, Besançon, Franche-Comte, France
Background/Purpose: The management of spondyloarthritis. (SpA) includes controlling disease activity as well as comorbidities such as metabolic syndrome. Metabolic syndrome can be associated with metabolic…
Abstract Number: 2687 • ACR Convergence 2025
Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
Lihi Eder¹, Uma Scher², Kyra Chen³, Alexandra L. Rice³, Sydney Thib⁴ and Rebecca Haberman⁵, ¹University of Toronto, Toronto, ON, Canada, ²NYU School of Medicine, Scarsdale, NY, ³NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, ⁴Women's College Research Institute, Women's College Hospital, Toronto, Canada, ⁵NYU Langone Health, New York, NY
Background/Purpose: Obesity is highly prevalent in psoriatic arthritis (PsA) and is associated with reduced therapeutic response, worse disease outcomes, and increased cardiometabolic risk. Glucagon-like peptide-1…
Abstract Number: 2200 • ACR Convergence 2025
Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study
Sinead Maguire¹, John Snelgrove², Priscila Pequeno³, Michael Paterson⁴, Fangyun Wu⁴, Laura Passalent⁵, Anthony Perruccio⁶, Dharini Mahendira⁷, Elie Karam⁸, Robert Inman⁹ and Nigil Haroon¹⁰, ¹Our Lady's Hospital Navan, Dublin, Dublin, Ireland, ²Mount Sinai Hospital, Toronto, Canada, ³Institute for Clinical Evaluative Sciences (ICES), Toronto, Canada, ⁴Institute of Clinical & Evaluative Sciences, Toronto, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute and Krembil Research Institute, University Health Network, Toronto, Canada, ⁷St Michael's Hospital, Toronto, Canada, ⁸Canadian Spondylitis Association, Toronto, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Women with axial spondyloarthritis (axSpA) are frequently diagnosed during their childbearing years. While studies have reported on pregnancy complications in this population, deriving generalizable…
Abstract Number: 0553 • ACR Convergence 2025
Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Zeyu Tang¹ and Abhijeet Danve², ¹Yale School of Medicine, New Haven, CT, ²Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Lack of timely rheumatology referral of chronic back pain (CBP) patients with suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis. We…
Abstract Number: 0585 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
Shikha Singla¹, Linda Grinnell-Merrick², Weibin Bao³, Artem Zharkov⁴ and Abhijeet Danve⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic disease characterized by inflammatory low back pain and is often accompanied by inflammation of the peripheral joints and…
Abstract Number: 2676 • ACR Convergence 2025
Tofacitinib in Juvenile spondyloarthropathy: clinical efficacy, impact on biomarkers and comparison with Adalimumab
Anu Balakrishnan¹, Asif Khan², Shivika Guleria³, Fareha Umam⁴, Naveen R⁵, Priyansh Jain², Lekshmi Minikumari Rahulan², Rudrarpan Chatterjee⁶ and Amita Aggarwal⁷, ¹Sanjay Gandhi Post Graduate Institute, India, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ³SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁴Dept of Clinical Immunology and Rheumatology, SGPGIMS, Lucknow, Uttar Pradesh, India, ⁵Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Tofacitinib is a JAK inhibitor that has been approved for treatment of polyarticular Juvenile idiopathic arthritis. However, data on its use in juvenile spondyloarthropathy…
Abstract Number: 2131 • ACR Convergence 2025
Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype
Austen Grooms¹, Ioannis Karageorgiou², Kerry Mychaliska² and James Birmingham³, ¹William Beaumont University Hospital, Auburn Hills, MI, ²William Beaumont University Hospital, Royal Oak, MI, ³River City Rheumatology, Grand Rapids, MI
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory disease primarily affecting muscle, skin, and vasculature. Characterized by muscle weakness, distinctive skin lesions, and autoantibodies, it…
Abstract Number: 0548 • ACR Convergence 2025
Artificial Intelligence in Axial Spondyloarthritis Diagnosis: Integrating Structural and Inflammatory Lesionsfrom Sacrum MRI
Seonyoung Kang¹, Yunseo Kim², Seulkee Lee³, Myung Jin Chung⁴, Hyungjin Kim⁵, Jaejoon Lee⁴, Hakje Yoo⁶ and Hoon-Suk Cha⁴, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea, ²Samsung Medical Center, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea, ³Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea
Background/Purpose: The Assessment of SpondyloArthritis International Society (ASAS) criteria define positive MRI findings based on the presence of bone marrow edema (BME) in the sacroiliac…
Abstract Number: 2636 • ACR Convergence 2025
Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Raj Sengupta¹, Anthony Marotta², Walter P. Maksymowych³, Charlotte Cavill⁴, Stephen Bleakley² and Norma Biln⁵, ¹Royal National Hospital for Rheumatic Diseases, Bath, England, United Kingdom, ²Augurex Life Sciences Corp, Vancouver, BC, Canada, ³Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁴Royal United Hospitals Bath NHS Foundation Trust, Bath, England, United Kingdom, ⁵Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: People with axial spondyloarthritis (axSpA), typically present with persistent back pain and experience up to a 10-year diagnostic delay that may lead to irreversible…
Abstract Number: 1959 • ACR Convergence 2025
The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis
Lihi Eder¹, Ricardo Acayaba de Toledo², Catherine Bakewell³, Philippe Carron⁴, Basant Elnady⁵, Amir Haddad⁶, Arthur Kavanaugh⁷, Fahmeen J. Afgani⁸, Arnon Katz⁹, Minna Kohler¹⁰, josefina marin¹¹, Nam Nguyen¹², Adrien NZEUSSEU TOUKAP¹³, Ari Polachek¹⁴, Ernesto Rodriguez¹⁵, Marcos Rosemffet¹⁶, Abha Singh¹⁷, Maria S. Stoenoiu¹⁸, Agnes Szentpetery¹⁹, Iliara Tinazzi²⁰, Janeth Yinh²¹, Mu Yang²², Richard Cook²², Gurjit Kaeley²³ and Sibel Aydin²⁴, ¹University of Toronto, Toronto, ON, Canada, ²Centro Integrado de Pesquisas (CIP) do Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil, ³Intermountain Healthcare Medical Group, Salt Lake City, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵Research Centre at Al Hada Armed Forces Hospital, Cairo, Egypt, ⁶Carmel Medical Center, Haifa, Israel, ⁷University of California, San Diego, School of Medicine, San Diego, CA, ⁸Women's College Hospital, Toronto, Canada, ⁹GRAPPA, Seattle, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹Hospital Universitario Rey Juan Carlos, Madrid, Spain, ¹²University of Toronto, Toronto, Canada, ¹³Cliniques Universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium, ¹⁴Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, ¹⁵Florida Medical Clinic, Tampa, ¹⁶Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ¹⁷Altman Clinical and Translational Research Institute, University of California San Diego, San Diego, CA, ¹⁸Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁹Uppsala University Hospital, Djursholm, Sweden, ²⁰Ospedale Sacro Cuore-Don Calabria, Verona, Italy, ²¹Massachusetts General Hospital, Boston, MA, ²²University of Waterloo, Waterloo, Canada, ²³UF COM-J, Ponte Vedra Beach, FL, ²⁴Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Enthesitis is a key lesion in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a novel sonographic…
Abstract Number: 0541 • ACR Convergence 2025
Inflammatory Back Pain Is Not Associated With HLA-B27 Positivity or CRP Levels in a Nationally Representative U.S. Population
Mark Hwang¹, Seokhun Kim², Charles Green¹, Charles Dillon³, Shervin Assassi⁴, Michael Weisman⁵ and John Reveille⁶, ¹UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³NIH, Bethesda, MD, ⁴Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁵Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁶Department of Medicine, University of Texas Medical Center, Houston, TX
Background/Purpose: Inflammatory back pain (IBP) is a hallmark symptom of axial spondyloarthritis (axSpA) and is frequently used as a clinical entry point for further evaluation,…
Abstract Number: 2637 • ACR Convergence 2025
Initial Phospholipid Transferase Activity Is Predictive of Five-Year Sacroiliac Radiographic Progression in Axial Spondyloarthritis: Findings From the DESIR Cohort
Frank Verhoeven¹, Olivier Fakih¹, Sophie Hecquet², anne tournadre³, jean Paul Pais de Barros⁴, Céline Delougeot⁵, Clément Prati¹ and WENDLING Daniel¹, ¹CHU de Besançon, Besançon, Franche-Comte, France, ²Rheumatology department, Cochin hospital, Paris, France, ³CHU Clermont ferrand, Clermont-Ferrand, France, ⁴Labex lipstick, Dijon, France, ⁵université Marie et Louis Pasteur, Besancon
Background/Purpose: The pathophysiology of axial spondyloarthritis (axSpA) involves the gut-joint axis. Recent studies suggest more active disease in cases of gut involvement.The objective of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].